|
|
Ace-DEX |
|
Vaxjo ID |
476 |
|
Vaccine Adjuvant Name |
Ace-DEX |
|
Adjuvant VO ID |
VO_0005753
|
|
Description |
biopolymer designed for microparticle formulation that induce Th1/Th2 balanced response |
|
Stage of Development |
Research |
|
Location Licensed |
United States |
|
Host Species for Testing |
Mouse |
|
Components |
Acetelated dextran (Ace-DEX) and either cyclic GMP-AMP (cGAMP) or resiquimod (R848) |
|
Structure |
acetal groups are formed along the glucose backbone of dextran |
|
Preparation |
encapsulations were fabricated using electrospray |
|
Function |
Type: particulate antigen delivery system vaccine adjuvant. Induces Th1/Th2 mixed immune profile. enhanced antigen uptake, innate immune activation |
| References |
Bachelder et al., 2017: Bachelder EM, Pino EN, Ainslie KM. Acetalated Dextran: A Tunable and Acid-Labile Biopolymer with Facile Synthesis and a Range of Applications. Chemical reviews. 2017; 117(3); 1915-1926. [PubMed: 28032507].
Collier et al., 2018: Collier MA, Junkins RD, Gallovic MD, Johnson BM, Johnson MM, Macintyre AN, Sempowski GD, Bachelder EM, Ting JP, Ainslie KM. Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists. Molecular pharmaceutics. 2018; 15(11); 4933-4946. [PubMed: 30281314].
|
|
